HomeAI · summaries
Storia in 3 fonti
Sun Pharma gets Brazil nod for Semaglutide
Sun Pharma receives ANVISA approval to launch semaglutide in Brazil, expanding diabetes treatment options in a $413 million market.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
swissinfo.ch
Brazil approves generic GLP-1 drug sold by Swiss firm Sandoz
Brazil approves Sandoz-marketed Owozy for type 2 diabetes, with launch planned in late 2026.
- ·
thehindubusinessline.com
Sun Pharma gets green signal on semaglutide in Brazil, its second export market
Sun Pharma gains ANVISA approval to launch semaglutide in Brazil, partnering with Hypera Pharma for diabetes treatment.
